Skip to main content

Purified natural and recombinant allergens with novel th1 adjuvants for use in allergen-specific immunotherapy

Objective

Approximately 20% of the world's population displays allergy symptoms (rhinitis, conjunctivitis, asthma) in response to common substances such as pollen, mite, and pet dander. Specific immunotherapy (SIT) is the only treatment that attacks the root of allergic disease rather than merely alleviating its symptoms. Many researchers believe that this approach may one daybed used during the first years of life to block the progression of respiratory allergy. However, the allergen extracts currently used for immunotherapy are crude, ill-defined preparations. As result, the outcome of SIT can be unpredictable and carries with it the risk of side effects and serious adverse reactions. Obviously SIT can never be used for preventive vaccination purposes in children and will only be used to treat the most serious allergy cases until these risks are eliminated. This emphasizes the need to search for novel forms of safer immunotherapytreatments. This project proposes to develop new, well-defined and standardized immunotherapeutics with reduced anaphylactic potential for the treatment of four common allergies: grass pollen, tree pollen, and house dust mite and cat dander.

Funding Scheme

EAW - Exploratory awards

Coordinator

S.A. BIOPHADY N.V.
Address
86, Antoine Nifsstraat
1070 Bruxelles
Belgium

Participants (1)

CITEQ B.V.
Netherlands
Address
Turftorenstraat 12
9712 BP Groningen